Rifampicin-resistant tuberculosis national study
Part of Infections clinical trials.
This study gathers information from patients treated for multidrug-resistant or rifampicin-resistant tuberculosis in France. It helps doctors learn more about the disease and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are being treated for multidrug-resistant or rifampicin-resistant tuberculosis.
- You are receiving care at one of the participating centers in France.
- You agree to have your medical information used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a shorter six-month treatment for tuberculosis that is resistant to rifampicin, a common antibiotic. The goal is to make treatment easier and possibly safer while still being effective.
This study follows people starting treatment for tuberculosis (TB) in France to learn more about the disease and its treatment. If you have been diagnosed with TB and started treatment within the last 8 days, you may be able to join.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This study follows people who are newly treated for tuberculosis, including lung and non-lung (extra-lung) cases. It may help doctors better understand tuberculosis and how patients respond after treatment starts.
This study tests different treatment plans for people with tuberculosis (TB) that can be cured with standard medicines. It aims to find the best treatment for each person based on their risk score, which may lead to shorter or more effective treatment.
This trial tests a new 6-month treatment for people with multidrug-resistant tuberculosis (MDR-TB). It aims to see if this shorter treatment works well and can be used in France, offering a quicker option for recovery.
Hear when a new Rifampicin-resistant Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.